Volume 27, Number 5—May 2021
Research
Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands
Table 3
0–3 d past onset |
0–7 d past onset |
All |
|||||||
---|---|---|---|---|---|---|---|---|---|
Characteristic | No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) |
|||
Clinical sensitivity | 319 | 94.9 (86.1–98.3) | 650 | 90.6 (84.3–94.6) | 970 | 84.9 (79.1–89.4) | |||
Sensitivity Ct <30 | 316 | 98.2 (90.6–99.9) | 640 | 95.8 (90.5–98.2) | 943 | 94.3 (89.6–0.97) | |||
Sensitivity Ct <25 |
305 |
100 (92.1–100) |
608 |
98.8 (93.7–99.9) |
897 |
99.1 (95.2–100) |
|||
Clinical specificity |
319 |
99.6 (97.9-100) |
650 |
99.6 (98.6-99.9) |
970 |
99.5 (98.7-99.8) |
|||
Positive predictive value | NA | 98.2 (90.7–99.9) | NA | 98.3 (94.0–99.5) | NA | 97.5 (93.8–99.0) | |||
Negative predictive value | NA | 98.9 (96.7–99.6) | NA | 97.7 (96.1–98.7) | NA | 96.5 (95.0–97.6) |
*Sensitivity and specificity of Ag RDT was calculated based on reverse transcription PCR results and days since symptoms onset. Positive and negative predictive values were calculated using 19.2% prevalence setting. Ag RDT, rapid antigen detection test; Ct, cycle threshold; NA, not applicable.
Page created: March 16, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.